ArticleNPJ biofilms and microbiomes2021
The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis.
Article in NPJ biofilms and microbiomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Glycoside hydrolases enhance antibiotic activity againstMicrobiology spectrum · 2026Article
- Review
- Beyond the matrix: rethinking antibiotic tolerance in CF biofilms using 3D models.NPJ biofilms and microbiomes · 2025Article
- Biofilm Formation ofMicroorganisms · 2025Review
- Article
- Production and characterization of exopolysaccharides from Pseudomonas aeruginosa AG01 with some medical potential applications.Microbial cell factories · 2025Article
- Diversification ofMicroorganisms · 2025Article
- Biofilm Resilience: Molecular Mechanisms Driving Antibiotic Resistance in Clinical Contexts.Biology · 2025Review
- Review
- Lack of correlation betweenHeliyon · 2024Article
- Insights onMicroorganisms · 2024Article
- Predictive modeling of antibiotic eradication therapy success for new-onset Pseudomonas aeruginosa pulmonary infections in children with cystic fibrosis.PLoS computational biology · 2023Article
- Antibacterial and Antibiofilm Effects of Lactobacilli Strains against Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2023Article
- Anti-glycan monoclonal antibodies: Basic research and clinical applications.Current opinion in chemical biology · 2023Review
- The Pseudomonas aeruginosa Biofilm Matrix Protein CdrA Has Similarities to Other Fibrillar Adhesin Proteins.Journal of bacteriology · 2023Review
- How Three Self-Secreted Biofilm Exopolysaccharides ofInternational journal of molecular sciences · 2023Review
- Combination of Meropenem and Zinc Oxide Nanoparticles; Antimicrobial Synergism, Exaggerated Antibiofilm Activity, and Efficient Therapeutic Strategy against Bacterial Keratitis.Antibiotics (Basel, Switzerland) · 2022Article
- The changing landscape of the cystic fibrosis lung environment: From the perspective of Pseudomonas aeruginosa.Current opinion in pharmacology · 2022Review
- Chlorhexidine PromotesInternational journal of molecular sciences · 2022Article
- Pseudomonas aeruginosa polysaccharide Psl supports airway microbial community development.The ISME journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
Abstract
The exopolysaccharide Psl contributes to biofilm structure and antibiotic tolerance and may play a role in the failure to eradicate Pseudomonas aeruginosa from cystic fibrosis (CF) airways. The study objective was to determine whether there were any differences in Psl in P. aeruginosa isolates that were successfully eradicated compared to those that persisted, despite inhaled tobramycin treatment, in children with CF. Initial P. aeruginosa isolates were collected from children with CF undergoing eradication treatment, grown as biofilms and labeled with 3 anti-Psl monoclonal antibodies (Cam003/Psl0096, WapR001, WapR016) before confocal microscopy visualization. When grown as biofilms, P. aeruginosa isolates from children who failed antibiotic eradication therapy, had significantly increased Psl0096 binding compared to isolates from those who cleared P. aeruginosa. This was confirmed in P. aeruginosa isolates from the SickKids Eradication Cohort as well as the Early Pseudomonas Infection Control (EPIC) trial. Increased anti-Psl antibody binding was associated with bacterial aggregation and tobramycin tolerance. The biofilm matrix represents a potential therapeutic target to improve P. aeruginosa eradication treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.